Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial
- PMID: 26580307
- DOI: 10.1001/jamapsychiatry.2015.2235
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial
Erratum in
-
Omission in Byline and Errors in Affiliation and Table.JAMA Psychiatry. 2016 Jan;73(1):90. doi: 10.1001/jamapsychiatry.2015.3150. JAMA Psychiatry. 2016. PMID: 26747291 No abstract available.
Abstract
Importance: Bright light therapy is an evidence-based treatment for seasonal depression, but there is limited evidence for its efficacy in nonseasonal major depressive disorder (MDD).
Objective: To determine the efficacy of light treatment, in monotherapy and in combination with fluoxetine hydrochloride, compared with a sham-placebo condition in adults with nonseasonal MDD.
Design, setting, and participants: Randomized, double-blind, placebo- and sham-controlled, 8-week trial in adults (aged 19-60 years) with MDD of at least moderate severity in outpatient psychiatry clinics in academic medical centers. Data were collected from October 7, 2009, to March 11, 2014. Analysis was based on modified intent to treat (randomized patients with ≥1 follow-up rating).
Interventions: Patients were randomly assigned to (1) light monotherapy (active 10,000-lux fluorescent white light box for 30 min/d in the early morning plus placebo pill); (2) antidepressant monotherapy (inactive negative ion generator for 30 min/d plus fluoxetine hydrochloride, 20 mg/d); (3) combination light and antidepressant; or (4) placebo (inactive negative ion generator plus placebo pill).
Main outcomes and measures: Change score on the Montgomery-��sberg Depression Rating Scale (MADRS) from baseline to the 8-week end point. Secondary outcomes included response (≥50% reduction in MADRS score) and remission (MADRS score ≤10 at end point).
Results: A total of 122 patients were randomized (light monotherapy, 32; fluoxetine monotherapy, 31; combination therapy, 29; placebo, 30). The mean (SD) changes in MADRS score for the light, fluoxetine, combination, and placebo groups were 13.4 (7.5), 8.8 (9.9), 16.9 (9.2), and 6.5 (9.6), respectively. The combination (effect size [d] = 1.11; 95% CI, 0.54 to 1.64) and light monotherapy (d = 0.80; 95% CI, 0.28 to 1.31) were significantly superior to placebo in the MADRS change score, but fluoxetine monotherapy (d = 0.24; 95% CI, -0.27 to 0.74) was not superior to placebo. For the respective placebo, fluoxetine, light, and combination groups at the end point, response was achieved by 10 (33.3%), 9 (29.0%), 16 (50.0%), and 22 (75.9%) and remission was achieved by 9 (30.0%), 6 (19.4%), 14 (43.8%), and 17 (58.6%). Combination therapy was superior to placebo in MADRS response (β = 1.70; df = 1; P = .005) and remission (β = 1.33; df = 1; P = .02), with numbers needed to treat of 2.4 (95% CI, 1.6 to 5.8) and 3.5 (95% CI, 2.0 to 29.9), respectively. All treatments were generally well tolerated, with few significant differences in treatment-emergent adverse events.
Conclusions and relevance: Bright light treatment, both as monotherapy and in combination with fluoxetine, was efficacious and well tolerated in the treatment of adults with nonseasonal MDD. The combination treatment had the most consistent effects.
Trial registration: clinicaltrials.gov Identifier: NCT00958204.
Comment in
-
Mindfulness-Based Stress Reduction for Posttraumatic Stress Disorder, Coffee Consumption and Mortality, Phytoestrogens for Menopause, Light Therapy for Non-Seasonal Depression, Electroacupuncture for Labor Pain.Explore (NY). 2016 May-Jun;12(3):210-4. doi: 10.1016/j.explore.2016.02.013. Epub 2016 Mar 2. Explore (NY). 2016. PMID: 27061036 No abstract available.
Similar articles
-
Appetitive Symptoms Differentially Predict Treatment Response to Fluoxetine, Light, and Placebo in Nonseasonal Major Depression.J Clin Psychiatry. 2018 Jul 24;79(4):17m11856. doi: 10.4088/JCP.17m11856. J Clin Psychiatry. 2018. PMID: 30063303 Clinical Trial.
-
Novel Augmentation Strategies in Major Depression.Dan Med J. 2017 Apr;64(4):B5338. Dan Med J. 2017. PMID: 28385173 Review.
-
Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.JAMA Psychiatry. 2016 Jul 1;73(7):675-84. doi: 10.1001/jamapsychiatry.2016.0838. JAMA Psychiatry. 2016. PMID: 27304433 Clinical Trial.
-
Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.Clin Ther. 2009 Jun;31 Pt 1:1405-23. doi: 10.1016/j.clinthera.2009.07.006. Clin Ther. 2009. PMID: 19698901 Clinical Trial.
-
Seasonal affective disorder: Do non-drug interventions such as light and vitamin therapy lead to better results? IQWiG Reports – Commission No. HT18-04 [Internet].Cologne (Germany): Institute for Quality and Efficiency in Health Care (IQWiG); 2021 Apr 14. Cologne (Germany): Institute for Quality and Efficiency in Health Care (IQWiG); 2021 Apr 14. PMID: 33956415 Free Books & Documents. Review.
Cited by
-
A Light-Responsive Neural Circuit Suppresses Feeding.J Neurosci. 2024 Jul 24;44(30):e2192232024. doi: 10.1523/JNEUROSCI.2192-23.2024. J Neurosci. 2024. PMID: 38897723
-
Commentary: Retinal electrophysiology in central nervous system disorders. A review of human and mouse studies.Front Neurosci. 2024 May 7;18:1400923. doi: 10.3389/fnins.2024.1400923. eCollection 2024. Front Neurosci. 2024. PMID: 38774787 Free PMC article. No abstract available.
-
Bright Light Therapy for Major Depressive Disorder in Adolescent Outpatients: A Preliminary Study.Clocks Sleep. 2024 Jan 30;6(1):56-71. doi: 10.3390/clockssleep6010005. Clocks Sleep. 2024. PMID: 38390946 Free PMC article.
-
Major depressive disorder: hypothesis, mechanism, prevention and treatment.Signal Transduct Target Ther. 2024 Feb 9;9(1):30. doi: 10.1038/s41392-024-01738-y. Signal Transduct Target Ther. 2024. PMID: 38331979 Free PMC article. Review.
-
Selecting, implementing and evaluating control and placebo conditions in light therapy and light-based interventions.Ann Med. 2024 Dec;56(1):2298875. doi: 10.1080/07853890.2023.2298875. Epub 2024 Feb 8. Ann Med. 2024. PMID: 38329797 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous